In Canada, the average health benefits cost trend for 2025 is estimated to be 7.4 per cent, up from five per cent in 2024, according to a new report by Aon. It found the top medical conditions driving health benefits plan costs are diabetes, autoimmune diseases (excluding diabetes), mental health, lung disorders/respiratory and cardiovascular and […]
In light of the federal government developing a national pharmacare program, it’s important it considers the implementation of a national drug pooling program for private payers, says one expert. “If the government is going to invest in a universal drug program, it needs to have two main objectives,” said Edward Sabat, partner at The Consulting […]
Ontario’s Ministry of Health is consulting on the role of preferred pharmacy networks in the province’s employer-sponsored drug insurance sector to determine how these agreements impact plan members’ costs, choice, accessibility and access to medicine and quality of care. In its draft consultation paper, the ministry said a common concern among consumers is when PPNs are closed and […]
U.S. employers are projecting health benefits costs to increase by eight per cent for 2025, up from seven per cent in 2023, according to a new survey by the International Foundation of Employee Benefit Plans. It found employers cited several factors in rising costs, including catastrophic claims (20 per cent, up from 19 per cent […]
The World Health Organization defines a rare disease as having a prevalence of 65 or less per 100,000 individuals. It recognizes some 5,500 rare diseases, the majority being of genetic origin and often life-threatening. Medical research has yielded significant drug development for the treatment of rare diseases, increasing life expectancy and improving quality of life. However, […]
An article outlining the implications of a single-payer universal pharmacare system was the most-read story on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investmnet stories of the past week: 1. Sounding Board: What plan sponsors should know about pharmacare 2. Meet the 2024 Workplace Benefits Awards judges 3. Mental-health claims by Canadians up […]
When considering whether to cover Wegovy, an obesity medication, it’s important for plan sponsors to weigh increased short-term costs with long-term savings, while considering alternative treatments that are also available, says Philippe Laplante, a principal at Eckler Ltd. Plan sponsors that decide to cover Wegovy, which launched in Canada last month, could see a significant cost […]
Institutional investors are navigating two massive innovations, namely artificial intelligence and artificial incretins, said Jennifer O’Hara Martin, global equity portfolio specialist at T. Rowe Price, during the Canadian Investment Review‘s 2024 Global Investment Conference in April. People tend to compare the current AI trend to the technology bubble of the 2000s and while its infrastructure is similar, […]
An article on legal challenges filed against the federal government’s hybrid work mandate for public service employees was the most-read story on BenefitsCanada.com this week. Here are the top five human resources, benefits, pension and investment stories of the past week: 1. Unions representing federal public service workers file legal challenges against hybrid work mandate 2. Expert […]
While the concept behind the federal government’s universal pharmacare plan is well intentioned, the program would make a larger impact for employers by focusing on high-cost and specialty drugs, says Pam Martin, vice-president and senior consultant at Baynes & White Inc. In theory, the way that the government is rolling out the program in small […]